Last reviewed · How we verify
PENICILLIN G BENZATHINE
Penicillin G kills bacteria by inhibiting cell-wall peptidoglycan synthesis, making the cell wall unstable.
At a glance
| Generic name | PENICILLIN G BENZATHINE |
|---|---|
| Target | cell-wall peptidoglycan |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1952 |
Mechanism of action
Penicillin G works by stopping the bacteria from building their cell walls properly. This makes the cell walls weak and unable to protect the bacteria, leading to their death.
Approved indications
Boxed warnings
- WARNING NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS , ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the labeling. WARNING NOT FOR INTRAVENOUS USE. DO NOT INJECT INTRAVENOUSLY OR ADMIX WITH OTHER INTRAVENOUS SOLUTIONS. THERE HAVE BEEN REPORTS OF INADVERTENT INTRAVENOUS ADMINISTRATION OF PENICILLIN G BENZATHINE WHICH HAS BEEN ASSOCIATED WITH CARDIORESPIRATORY ARREST AND DEATH. Prior to administration of this drug, carefully read the WARNINGS , ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the labeling.
Common side effects
- Injection site pain
- Skin eruptions (maculopapular to exfoliative dermatitis)
- Urticaria
- Fever
- Chills
- Nausea
- Vomiting
- Headache
- Dizziness
- Injection site inflammation
- Pruritus
- Edema
Serious adverse events
- Anaphylaxis including shock and death
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Acute myocardial ischemia with or without myocardial infarction (Kounis syndrome)
- Pseudomembranous colitis
- Cardiac arrest
- Pulmonary embolism
- Transverse myelitis
- Rhabdomyolysis
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics (PHASE4)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients. (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PENICILLIN G BENZATHINE CI brief — competitive landscape report
- PENICILLIN G BENZATHINE updates RSS · CI watch RSS